Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ORMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $155.24M
- P/E (TTM)
- 1.05
- EPS (TTM)
- $3.41
- Dividend yield
- 7.00% ($0.00)
- Ex-dividend date
- Jan 16, 2026
- 52-week range
- 2.52 – 5.47
- Day range
- 3.54 – 3.71
- Volume / Avg
- 285.67K / 173.38K
- Beta
- —
- Shares outstanding
- 43.49M
52-week range
ORMP stock today
Shares of Oramed Pharmaceuticals (ORMP) finished lower on Nov 20 at $3.57, a drop of 3.25% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, ORMP sits in the middle of its 52-week range of $2.52 to $5.47: 34.7% below the high, set on Aug 27, 2026 and 41.7% above the low. ORMP is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.4%.
Oramed Pharmaceuticals trades at 1.0x its trailing twelve-month earnings per share of $3.41.
Summary generated from market data by MetaCap's automated system. Methodology
About Oramed Pharmaceuticals
Company profileOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nadav Kidron Esq.
- Headquarters
- New York, NY
- Website
- oramed.com
Financial highlights
Full financialsIn fiscal 2025, Oramed Pharmaceuticals generated $2.0 million in revenue. Net income was $64.0 million, for a net margin of 3202.5% versus a median of -637.6% in the prior 5 years. Gross margin was 0.7% and operating margin -754.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.00M | — | $1.34M | $2.70M | $2.70M |
| Growth | — | — | -50.43% | 0.00% | -0.26% |
| Net income | $64.05M | $-19.06M | $5.09M | $-36.56M | $-22.99M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | $0.78 |
Analyst forecast
ForecastConsensus
none
Avg. price target
$7.00+96.08%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.43 vs $0.43
- Surprise
- 0.00%
Dividends
Dividend history- Annual dividend
- $0.00
- Dividend yield
- 7.00%
- Last payment
- $0.25
- Ex-dividend date
- Jan 16, 2026
ORMP news
All ORMP newsOramed Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs ORMP |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs ORMP |
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs ORMP |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs ORMP |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs ORMP |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs ORMP |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs ORMP |
| ABEOAbeona Therapeutics Inc. | 2.42 | -1.22% | $165.31M | vs ORMP |
Indexes, lists and sector
Oramed Pharmaceuticals stock FAQ
What is Oramed Pharmaceuticals's stock price today?
ORMP last traded at $3.57 as of Nov 20, 4:00 PM EST, down 3.25% on the day. Prices are delayed at least 15 minutes.
Does Oramed Pharmaceuticals pay a dividend?
Yes. Oramed Pharmaceuticals pays $0.00 per share annually, a 7.00% yield. The most recent dividend of $0.25 had an ex-dividend date of Jan 16, 2026.
What is ORMP's P/E ratio?
ORMP trades at a trailing P/E ratio of 1.05.
Who is Oramed Pharmaceuticals's CEO?
Mr. Nadav Kidron Esq. is the chief executive officer of Oramed Pharmaceuticals Inc..
Has ORMP ever split its stock?
Yes. The most recent ORMP stock split was a 1-for-12 split on Jan 23, 2013.
What is the ORMP 52-week high?
The 52-week high for ORMP is $5.47 and the 52-week low is $2.52. The stock is currently 34.7% below its high.